{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:38:37Z","timestamp":1793234317967,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.clml.2019.10.004","type":"journal-article","created":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T10:03:19Z","timestamp":1570960999000},"page":"87-97.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1754-1204","authenticated-orcid":false,"given":"Somedeb","family":"Ball","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avash","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1701-9800","authenticated-orcid":false,"given":"Wasawat","family":"Vutthikraivit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy J.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Hardwicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.10.004_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.10.004_bib2","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2019.10.004_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2162-3619-3-4","article-title":"Ibrutinib for B cell malignancies","volume":"3","author":"Novero","year":"2014","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.clml.2019.10.004_bib5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","article-title":"The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis","volume":"128","author":"Leong","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.10.004_bib6","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/bloodadvances.2016001883","article-title":"Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis","volume":"1","author":"Caron","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2019.10.004_bib7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","article-title":"Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2019.10.004_bib8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/ejh.13020","article-title":"Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies","volume":"100","author":"Tillman","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2019.10.004_bib9","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1182\/blood-2018-02-832154","article-title":"Ibrutinib and fungus: an invasive concern","volume":"131","author":"Rogers","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.10.004_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00262-005-0015-8","article-title":"Immune defects in patients with chronic lymphocytic leukemia","volume":"55","author":"Ravandi","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clml.2019.10.004_bib11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.10.004_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bjh.15146","article-title":"Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in chronic lymphocytic leukaemia","volume":"181","author":"Crassini","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.10.004_bib13","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.10.004_bib14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/ejh.13098","article-title":"Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?","volume":"101","author":"Ball","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2019.10.004_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.clml.2019.10.004_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2288-4-17","article-title":"Meta-analytic methods for pooling rates when follow-up duration varies: a case study","volume":"4","author":"Guevara","year":"2004","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clml.2019.10.004_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.10.004_bib19","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.10.004_bib20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.10.004_bib21","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/cam4.1337","article-title":"Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study","volume":"7","author":"Huang","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2019.10.004_bib22","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in waldenstrom\u2019s macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.10.004_bib23","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","article-title":"Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study","volume":"32","author":"Rule","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.10.004_bib24","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.10.004_bib26","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1158\/1078-0432.CCR-14-0010","article-title":"Ibrutinib for the treatment of mantle cell lymphoma","volume":"20","author":"Herrera","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2019.10.004_bib27","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood-2016-06-722991","article-title":"Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib","volume":"128","author":"Ahn","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.10.004_bib28","first-page":"2018","article-title":"Cryptococcus neoformans empyema in a patient receiving ibrutinib for diffuse large B-cell lymphoma and a review of the literature","author":"Swan","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.clml.2019.10.004_bib29","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00277-017-2964-3","article-title":"Staphylococcus aureus meningitis in a patient with mantle cell lymphoma under treatment with ibrutinib","volume":"96","author":"Diamantopoulos","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.10.004_bib30","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00277-017-2944-7","article-title":"Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia","volume":"96","author":"Chan","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.10.004_bib31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/10428194.2017.1347931","article-title":"Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies","volume":"59","author":"Williams","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"10.1016\/j.clml.2019.10.004_bib32","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood.V130.Suppl_1.830.830","article-title":"Incidence and type of opportunistic infections during ibrutinib treatment at a single academic center","volume":"130","author":"Rogers","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.10.004_bib33","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.10.004_bib34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3816\/CLM.2009.n.071","article-title":"Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis","volume":"9","author":"Morrison","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2019.10.004_bib35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.15252\/emmm.201404556","article-title":"Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus","volume":"7","author":"Herbst","year":"2015","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.clml.2019.10.004_bib36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41408-018-0136-x","article-title":"Effect of the BTK inhibitor ibrutinib on macrophage- and gammadelta T cell-mediated response against Mycobacterium tuberculosis","volume":"8","author":"Colado","year":"2018","journal-title":"Blood Cancer J"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019320166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019320166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:52Z","timestamp":1761870892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019320166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S2152265019320166"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.10.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}